| HOME >> BIOLOGY >> TECHNOLOGY |
All statements that address expectations or projections about the future, including without limitation, statements about the Company's strategy for growth, product development, product launches, regulatory approvals, market position, market share increases, acquisitions, revenues, expenditures and other financial results, are forward-looking statements.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following: (1)
changes in the current and future business environment, including interest
rates and capital and consumer spending; (2) the difficulty of predicting
FDA approvals, including timing, and that any period of exclusivity may not
be realized; (3) acceptance and demand for new pharmaceutical products; (4)
the impact of competitive products and pricing, including as a result of
so-called authorized-generic drugs; (5) new product development and launch,
including the possibility that any product launch may be delayed or that
product acceptance may be less than anticipated; (6) reliance on key
strategic alliances; (7) the availability of raw materials and/or products
manufactured for the Company under contract manufacturing arrangements with
third parties; (8) the regulatory environment, including regulatory agency
and judicial actions and changes in applicable law or regulations; (9)
fluctuations in revenues; (10) the difficulty of predicting international
regulatory approval, including timing; (11) the difficulty of predicting
the pattern of inventory movements by the Company's customers; (12) the
impact of
'/>"/>
| SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Transdel Pharmaceuticals Closes $4 Million Financing
2. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
3. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Illinois Pharmaceutical Manufacturer Sued for Injuries to Kentucky Resident
5. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
6. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
7. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
9. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
11. Medimetriks Pharmaceuticals, Inc. Begins Operations
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |